Related Experiment Video
Updated: Jul 23, 2025

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Ameliorative effects of probiotics in AlCl3-induced mouse model of Alzheimer's disease
1Neurobiology Research Laboratory, Department of Healthcare Biotechnology, Atta ur Rahman School of Applied Biosciences, National University of Sciences and Technology (NUST), Islamabad, Pakistan.
Abstract:
In recent years, gut microbiome alterations have been linked with complex underlying mechanisms of neurodegenerative disorders including Alzheimer's disease (AD). The gut microbiota modulates gut brain axis by facilitating development of hypothalamic-pituitary-adrenal axis and synthesis of neuromodulators. The study was designed to unravel the effect of combined consumption of probiotics; Lactobacillus rhamnosus GG (LGG®) and Bifidobacterium BB-12 (BB-12®) (1 × 109 CFU) on AlCl3-induced AD mouse model in comparison with potent acetylcholine esterase inhibitor drug for AD, donepezil. Mice were randomly allocated to six different study groups (n = 8). Behavioral tests were conducted to assess effect of AlCl3 (300 mg/kg) and probiotics treatment on cognition and anxiety through Morris Water Maze (MWM), Novel Object Recognition (NOR), Elevated Plus Maze (EPM), and Y-maze. The results indicated that the combined probiotic treatment significantly (p < 0.0001) reduced anxiety-like behavior post AlCl3 exposure. The AlCl3 + LGG® and BB-12®-treated group showed significantly improved spatial (p < 0.0001) and recognition memory (p < 0.0001) in comparison to AlCl3-treated group. The expression status of inflammatory cytokines (TNF-α and IL-1β) was also normalized upon treatment with LGG® and BB-12® post AlCl3 exposure. Our findings indicated that the probiotics LGG® and BB-12® have strong potential to overcome neuroinflammatory imbalance, cognitive deficits and anxiety-like behavior, therefore can be considered as a combination therapy for AD through modulation of gut brain axis. KEY POINTS: • Bifidobacterium BB-12 and Lactobacillus rhamnosus GG were fed to AlCl3-induced Alzheimer's disease mice. • This combination of probiotics had remarkable ameliorating effects on anxiety, neuroinflammation and cognitive deficits. • These effects may suggest that combined consumption of these probiotics instigate potential mitigation of AD associated consequences through gut brain axis modulation.
Insights
This study shows that a combination of Lactobacillus rhamnosus GG and Bifidobacterium BB-12 probiotics can significantly reduce anxiety and improve memory in a mouse model of Alzheimer's disease (AD). These probiotics may offer a new therapeutic approach for AD by modulating the gut-brain axis.
Area of Science:
- Neuroscience
- Microbiology
- Pharmacology
Background:
- Gut microbiome alterations are increasingly linked to neurodegenerative disorders like Alzheimer's disease (AD).
- The gut microbiota influences the gut-brain axis, impacting neurological functions and mood regulation.
- Alzheimer's disease is characterized by cognitive deficits, anxiety, and neuroinflammation.
Purpose of the Study:
- To investigate the therapeutic potential of combined probiotics, Lactobacillus rhamnosus GG (LGG®) and Bifidobacterium BB-12 (BB-12®), in an aluminum chloride (AlCl3)-induced AD mouse model.
- To compare the effects of these probiotics with donepezil, a standard AD medication.
- To evaluate the impact of probiotics on cognitive function, anxiety-like behavior, and neuroinflammation.
Main Methods:
- Mice were induced with Alzheimer's disease using AlCl3 and treated with a combination of LGG® and BB-12® probiotics.
- Behavioral assessments including Morris Water Maze, Novel Object Recognition, Elevated Plus Maze, and Y-maze were performed.
- The expression levels of inflammatory cytokines (TNF-α and IL-1β) were analyzed.
Main Results:
- Combined probiotic treatment significantly reduced anxiety-like behaviors in AlCl3-treated mice.
- Probiotic administration markedly improved spatial and recognition memory compared to the AlCl3-only group.
- Treatment with LGG® and BB-12® normalized the expression of key inflammatory cytokines, TNF-α and IL-1β.
Conclusions:
- The combination of Lactobacillus rhamnosus GG and Bifidobacterium BB-12 demonstrates significant potential in ameliorating cognitive deficits and anxiety associated with Alzheimer's disease.
- These probiotics may serve as a viable complementary therapy for AD by modulating the gut-brain axis and reducing neuroinflammation.
- Further research into probiotic-based interventions for neurodegenerative diseases is warranted.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

